SUN Cui-cui, DONG Jing-wen, KUANG Ze-an, YIN Ming-xiao, LIU Xiao-jia, DENG Hong-bin. Research progresses on NLRP3 inflammasomes-induced anti-tumor immunityJ. Acta Pharmaceutica Sinica, 2022, 57(9): 2612-2621. DOI: 10.16438/j.0513-4870.2022-0520
Citation: SUN Cui-cui, DONG Jing-wen, KUANG Ze-an, YIN Ming-xiao, LIU Xiao-jia, DENG Hong-bin. Research progresses on NLRP3 inflammasomes-induced anti-tumor immunityJ. Acta Pharmaceutica Sinica, 2022, 57(9): 2612-2621. DOI: 10.16438/j.0513-4870.2022-0520

Research progresses on NLRP3 inflammasomes-induced anti-tumor immunity

  • More and more studies have shown that NOD-like receptor protein 3 (NLRP3) inflammasome has become the regulatory factor of inflammatory response and protective immunity, and the assembly and activation of NLRP3 inflammasomes are closely related to the anti-tumor immunity effect. Depending on the cell type and stimuli, activation of the NLRP3 inflammasome can induce immune cells to become polarized, hyperactive, or pyroptotic, releasing interleukin (IL)-1β and IL-18, which leads to cascade immune or inflammatory responses, and its role in tumor immunity has received extensive attention. Here, we review the mechanisms of the NLRP3 inflammasome enhancing CD8+ T cells-mediated anti-tumor immunity by inducing the pyroptosis of tumor cell, the pyroptosis or hyperactive state of dendritic cells (DCs), and the pyroptosis or polarization of the macrophages. Different anti-tumor immune roles of NLRP3 inflammasome activation in tumor cells and immune cells provide new directions for future research and may influence the development of next-generation immunotherapy.
  • loading

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return